Expected Outcome:
Objective:
This action aims to enhance the European genomic data infrastructure by supporting the deployment of advanced tools for data curation and use and its alignment with the European Health Data Space (EHDS). Data quality and volume are key success factors for health data infrastructures supported under the Digital Europe Programme, such as the one developed by the Genomic Data Infrastructure (GDI) project implementing the 1+ Million Genomes (1+MG) initiative of the Member States. The availability of thoroughly curated genomic data and related clinical and phenotypic information is a prerequisite for accelerating the move to the next level of multi-modal data modelling and deployment as well as health sector innovation in Europe. 1+MG and the projects implementing the initiative have worked and agreed on common data standards and ontologies, data quality criteria and thresholds, data inclusion policies and the necessary standard operational procedures. On that basis, data holders will need to quality-check and curate the datasets that they will be making available to 1+MG and EHDS (HealthData@EU) to ensure their interoperability and high value for users. Wide accessibility of the data and user-friendliness of the tools and services facilitating the access to data are critical success factors of the 1+MG data infrastructure. While such functionalities for research purposes have been already largely covered in the deployment project GDI, application in other use scenarios, in particular healthcare and public health policy, requires additional tools, application programming interfaces (APIs) and interfaces to address the corresponding specific user needs and requirements. The citizen perspective must be also factored in to ensure, through appropriate IT tools, full compliance with the General Data Protection Regulation (GDPR) rules regarding citizens’ rights on personal data protection. This action relates to the potential creation of a European Digital Infrastructure Consortium for genomic data (Genome EDIC) and supports the activities related to operating the 1+MG data infrastructure established with the support of Digital Europe under Work Programme 2021-2022 (GDI project), including its alignment with the requirements, technical specifications, and processes established by the EHDS Regulation to ensure a smooth functioning within the HealthData@EU infrastructure.
Scope:
Data tools for the 1+MG data infrastructure should be based on common standards and as automated as possible, and should enable data quality check at source, benchmarking, annotation and enhancement on the data provider end and by the operator of the data infrastructure, as appropriate. This covers the whole process of data inclusion, integration and access provision, as well as compliance assessment, risk management and data security assurance on the side of data infrastructure. All steps and functionalities should be designed to support the needs and requirements of three main use scenarios, i.e. research (largely already covered by the GDI project), and clinical care and public health policymaking. They should follow and implement the standards and procedures agreed within the 1+ Million Genomes initiative (1+MG Framework) and be compliant with the EHDS Regulation. For example, data curation tools should facilitate the description of datasets using a metadata standard compatible with the one required for the EU Dataset Catalogue of the EHDS (Health DCAT-AP), including its data quality and utility label as defined in the project QUANTUM. Metadata should also cover information about legal conditions and enablers for sharing the respective dataset. Moreover, the action should leverage best practices and strategies for linking clinical and genomic data at individual level, within the framework of EHDS where appropriate, to maximise access to data while preserving the security and privacy of data subjects (e.g. sampling, anonymisation and pseudonymisation techniques, data gap filling). Data minimisation tools should support compliance with the respective GDPR rules. Moreover, this action covers piloting and the deployment of tools, APIs and interfaces to provide high quality data services to the users of the 1+MG data infrastructure for healthcare and public health policy purposes as well as addressing any remaining user needs in research not yet covered by other projects. For example, APIs and interfaces for data discovery, and federated analysis and modelling in a secure processing environment will enable users to find, access and integrate the data at the required level of data protection safeguards to serve their projects, clinical questions or policy development. Adequate data de-identification/synthetisation methods and support to multi-modal data discovery and analysis across the data infrastructures (e.g. linking up with the Cancer Image Europe and HealthData@EU infrastructures) should also be considered and implemented. The tools delivered and deployed should be user-friendly and clearly support high uptake of the data infrastructures and their services. Furthermore, the action is expected to establish a citizen portal for 1+MG enabling citizens to exercise their GDPR rights, such as obtaining information about their data inclusion / processing and their legal basis, manage the consent, requesting data access, rectification or erasure. All solutions deployed by the project should be compatible with the Simpl middleware platform, where appropriate, and ensure interoperability with the HealthData@EU infrastructure. Tools related to authentication should be eIDAS-compliant. While fully respecting the prerogative of participants within the 1+MG data infrastructure to determine who can access what data and under which conditions, suitable links to the AI Factories should be envisaged. The project should include a description of data access and usage arrangements.
The EC is impact-driven: proposals must show how the project will:
Solve a major European or global societal challenge
Deliver measurable, lasting benefits for EU citizens
Produce outputs that can be used by policymakers, industry, or society
Align with Horizon Europe missions, priorities, and strategic agendas
Predictor: Clear, quantifiable, EU-level impact → strongest scoring factor.
Successful proposals show:
2–4 well-defined objectives linked to the Work Programme call text
Clearly articulated research questions or innovation goals
Logical, realistic expected outcomes and deliverables
Feasible scientific and technical approaches
Predictor: Balanced ambition + feasibility.
For RIA/IA/CSA or ERC-level grants, reviewers expect:
High novelty and innovation
Strong grounding in current state-of-the-art
Clear advancement beyond existing approaches
Solid theoretical or experimental foundations
Robust methodological design
Predictor: Scientific excellence is essential for competitive scoring.
EC proposals are consortium-driven (except ERC/EIC Accelerator).
High-scoring consortia:
Cover all needed competencies (science, industry, policy, ethics, dissemination)
Include SMEs, industry partners, NGOs, and public bodies when relevant
Are geographically diverse across EU Member States and Associated Countries
Demonstrate strong leadership and communication structures
Predictor: Well-constructed consortium with clear roles.
Evaluators look for a credible trajectory showing:
How research leads to specific outputs (data, tools, prototypes)
How outputs lead to uptake or use
How use produces societal, economic, scientific, or policy impact
Strong Key Performance Indicators (KPIs) and impact metrics
Predictor: Clearly mapped impact pathway.
Winning proposals have:
Well-designed Work Packages (WPs) with clear scope and responsibilities
Interdependencies identified and risk-mitigation strategies
Detailed milestones and deliverables
Feasible budget aligned with tasks
Strong project management plan
Predictor: High implementation quality boosts the “Excellence” and “Implementation” scores.
Especially critical for health, climate, digital, and social calls.
Proposals score higher when they link to:
EU Cancer Mission
EU Green Deal
Digital Europe strategy
EU Biodiversity Strategy
EU Health Union & One Health
Open Science & FAIR data mandates
Predictor: Clear alignment with EU policies.
EC values inclusivity:
Patient groups
Civil society organizations
Public sector bodies
Regulatory agencies
Citizen science components
Stakeholder letters of intent or commitment strengthen credibility.
Predictor: Engagement adds impact and relevance.
Mandatory components include:
FAIR Data Management Plan
Open access publications
Ethics self-assessment
GDPR compliance
Data security, governance, and ethical approvals
Animal-use reduction and justification (if applicable)
Predictor: Clear compliance with ethical and data obligations.
Budget must be:
Proportional to tasks
Transparent and reasonable
Efficiently distributed among partners
Free from padding or unjustified costs
Predictor: Realistic budgets improve Implementation scores.
| Pitfall | Why It Fails |
|---|---|
| Weak connection to Work Programme text | Immediate score reduction |
| Vague or generic impact statements | Poor Impact score |
| Overly ambitious, unrealistic scope | Feasibility concerns |
| Poorly structured consortium | Low Implementation score |
| No policy relevance | Weak strategic alignment |
| Lack of concrete KPIs or outcomes | Impact unclear |
| Weak data or ethics plan | Eligibility/score penalties |
| No exploitation or dissemination plan | Insufficient impact credibility |
| Budget misalignment | Reviewer distrust |
In order to be eligible, the applicants (beneficiaries and affiliated entities) must:
− be legal entities (public or private bodies)
− be established in one of the eligible countries, i.e.:
− EU Member States (including overseas countries and territories (OCTs))
− non-EU countries (except for topics with restrictions; see below):
− listed EEA countries and countries associated to the Digital Europe Programme (list of participating countries) Beneficiaries and affiliated entities must register in the Participant Register
— before submitting the proposal
— and will have to be validated by the Central Validation Service (REA Validation). For the validation, they will be requested to upload documents showing legal status and origin. Other entities may participate in other consortium roles, such as associated partners, subcontractors, third parties giving in-kind contributions, etc (see section 13)
Sponsor Institute/Organizations: European Commission
Sponsor Type: Corporate/Non-Profit
Address: Rue de la Loi 200 / Wetstraat 200, 1049 Brussels
Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.
Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.
Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.
Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.
Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.
Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.
Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.
Mar 03, 2026
Mar 03, 2026
$5,850,000
Affiliation: European Commission
Address: Rue de la Loi 200 / Wetstraat 200, 1049 Brussels
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.